This meta-analysis pooling available RCTs suggested that targeting lower Hb when treating dialysis patients with anemia decrease risk of fistula thrombosis and had no significant effect on increased risk of death, cardiovascular events, infectious diseases and transfusion. This evidence concerns the gene GSTM1 and anemia.